Medifast Faces Critical Earnings Test Amid Industry Upheaval

Medifast approaches a pivotal moment as it prepares to release third-quarter 2025 financial results after markets close on Monday. Market expectations reflect significant pessimism, with consensus estimates projecting a loss of $0.36 per share—representing a staggering 202 percent decline year-over-year. Revenue forecasts are equally concerning, anticipated at just $89.7 million, which would mark a 36 percent contraction.

While Medifast has historically exceeded expectations, beating both earnings and revenue estimates in 88 percent of cases over the past two years, current circumstances suggest this pattern may not continue. The company’s fundamental position has deteriorated substantially, with analysts maintaining a consistently negative outlook. Over the previous three months, no positive revisions to profit projections have emerged, while Read more...